Bronchoscopic lung volume reduction is a new and exciting area of research that hopes to provide a surgical alternative for those that suffer with emphysema. Emphysema is a debilitating disease that affects millions. Progressive dyspnea and the gradual loss of quality of life are characteristics of those afflicted. Current treatments are limited, with only oxygen therapy and lung volume reduction surgery having any impact on mortality. The latter carries a significant mortality and morbidity, and thus is not routinely performed. The pathophysiology of the disease argues that lung volume reduction by any means should be beneficial. With this in mind, we review the use of unidirectional valves, airway bypass, and biological sealants to produce bronchoscopic lung volume reduction. Newer technologies such as thermal vaporization and endobronchial coiling are also included. The benefits and associated risks of each modality are explored. Considerations and directions for future clinical trials are suggested.
C urrent medical treatments for emphysema include smoking cessation, bronchodilators (both anticholinergics and beta-agonists), corticosteroids, pulmonary rehabilitation, and long-term oxygen therapy (LTOT). Of these, LTOT is the only medical therapy demonstrated to improve COPD mortality. 1 It is estimated that 3.7 million Americans have emphysema predominant COPD. 2 Surgical procedures such as lung volume reduction surgery (LVRS) and lung transplantation have been demonstrated to improve both quality of life and mortality in patients with emphysema. 3 However, such interventions can only be offered to a few selected patients who meet clearly established criteria. 4 LVRS is associated with significant morbidity and mortality. Consequently, this has resulted in many patients declining this intervention, even when they qualify.
New endobronchial modalities attempting to achieve lung volume reduction have been developed, whereas others are still being studied. The goal of these endobronchial technologies are to offer the benefits of lung volume reduction to a greater number of patients whereas minimizing the associated risks of the current surgical approach. It is important to point out that whereas mortality benefits comparable to LVRS are desirable, improved quality of life and dyspnea relief are equally important endpoints. The endobronchial valve (EBV) is the first and most studied device used to attempt to achieve bronchoscopic lung volume reduction (BLVR). [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] Currently, 2 valve systems have been developed, the Zephyr Valve (Pulmonx, Redwood City, CA) and the Spiration Valve (Spiration Incorporated, Redmond, WA). Another innovative approach to BLVR makes use of an airway bypass system (Broncus Technologies Inc, Mountain View, CA) creating a noncollapsing extra-anatomic passageway, and thus connecting the distal lung to the larger airways. [15] [16] [17] [18] [19] [20] An alternative for achieving BLVR is via endobronchial application of a biologic sealant or remodeling system to produce "biologic lung volume reduction" (Aeris Therapeutics, Woburn, MA). This method has recently completed Phase 2 trials. 21 Several other endobronchial therapies are also being explored; however, reporting on these remains in abstract form only. 22, 23 The focus of this article is to provide a historical perspective of LVRS, briefly discuss the pathophysiology of emphysema as it relates to BLVR technologies, and review the available literature regarding endobronchial devices currently available or being developed to produce BLVR. Finally, we discuss the expected future applications of these endobronchial devices.
HISTORICAL PERSPECTIVE OF LVRS
Surgical treatment for emphysema was initially performed in the 1950s by Brantigan et al and revisited in the 1990s by Cooper et al. 24, 25 Initial publications were encouraging, and both patients and physicians felt that an effective therapy for emphysema had become available. As greater numbers of patients began to undergo surgery, morbidity and mortality varied among the centers providing this new procedure. The Healthcare Finance Administration placed a halt on reimbursement which, in turn, prompted the creation of the National Emphysema Treatment Trial (NETT) sponsored by the National Heart, Lung, and Blood Institute. NETT required that patients undergo strict eligibility requirements, including enrollment in pulmonary rehabilitation. NETT identified that patients with predominantly upper lobe heterogeneous emphysema and a low baseline exercise capacity were likely to receive the most benefit. Benefits included both short-and long-term survival advantage, increased exercise capacity, and improvement in quality of life based on the Saint Georges Respiratory Questionnaire (SGRQ), when compared with maximized medical therapy. 3 Patients with a forced expiratory volume in 1 second (FEV1) or diffusion capacity of lung for carbon monoxide (DLCO) of Ͻ20% were identified as being high risk for perioperative mortality. 4 The 90 day mortality in nonhigh risk patients was 5.2% versus 1.3% with medical therapy. Overall serious morbidity was 59%. Reoperation (7%) was primarily for persistent air leaks (3%) or bleeding (1%). Of patients undergoing LVRS, 22% to 28% remained in the hospital 30 days after surgery. 3 The cost of LVRS has been estimated to be about $60,000 per patient. 26 The results of NETT were fairly sobering to both physicians and patients. The mortality rate and cost associated with LVRS may be acceptable to some, but many patients with emphysema and the physicians that refer these patients are not willing to pursue this option unless an improved outcome can be guaranteed. As a result many physicians do not offer this option to their patients, and patients when offered often decline to undergo the procedure.
Subsequent analyses of NETT have suggested that the quality of life improvements associated with LVRS can be found in all subgroups except in those with nonupper lobe predominant emphysema and a high risk for perioperative mortality. 27 It is from these results that researchers have suggested that additional studies in LVRS should be considered focusing on appropriate endpoints related to palliation of symptoms and quality of life measurements balanced against associated morbidity and mortality. It is with some certainty that the inspiration and development of BLVR can be attributed to the quality of life improvements that have been demonstrated in patients undergoing LVRS.
PATHOPHYSIOLOGY RELATED TO ENDOBRONCHIAL TECHNOLOGY
Emphysema primarily affects distal airways with destruction of the terminal bronchi. There is a loss of the lung's elastic tethering with the distal alveoli becoming over-distended. With disease progression, there is destruction of the alveolar septae and pulmonary capillaries. Emphysema can be heterogeneous (predominant upper or lower lobe involvement) or homogeneous (diffuse). A loss of elastic recoil leads to expiratory airway collapse and subsequent lung hyperinflation. Hyperinflation leads to a reduction in the resting length of the respiratory muscles, which impairs contraction. As a result, resting tidal volume is reduced, leading to an increase in baseline respiratory rate. As patients begin to exercise, hyperinflation is magnified (dynamic hyperinflation), thus reducing exercise capacity. 28 Lobar enlargement from emphysema results in compensatory compression of adjacent lung tissue which decreases effective alveolar ventilation. Alveolar ventilation is additionally decreased in emphysema via a progressive loss in functional alveoli. Alveolar loss results in greater dead space ventilation, thus reducing ventilation to perfusion ratio (V/Q). When patients with emphysema exerted themselves, the distribution of blood flow to poorly ventilated alveoli increases. This further worsens ventilation to perfusion ratio.
LVRS has been demonstrated to reduce hyperinflation, restoring the resting length of the muscle fibers as well as improving alveolar ventilation by reversing the compressive effects of lobar enlargement. Additionally, the elimination of dead space ventilation has been demonstrated to improve shunt physiology in some of those undergoing LVRS. 29 Endobronchial technologies hope to duplicate the effects of LVRS by selectively treating areas of hyperinflation. Most of the current approaches to BLVR attempt to create distal airway collapse in targeted lung segments, producing atelectasis. It is assumed that volume loss in these targeted segments would lead to decreased hyperinflation, compensatory lobar enlargement in adjacent lobes, and reduced dead space ventilation.
Unfortunately, endobronchial approaches have identified that selective targeting of certain lung subsegments may or may not result in distal airway collapse primarily because of the presence of collateral ventilation (CV). In this regard, Kohn was the first to describe interalveolar pores. 30 Subsequently, bronchiolar-alveolar and interbronchiolar channels have been identified. 31, 32 Morrell et al suggested that segmental CV occurs to a much greater extent in the emphysematous lung than in the normal lung. CV, if present, can result in continued hyperinflation despite complete occlusion of the proximal segment. 33 CV does not affect the results of LVRS as the pores are removed with the diseased lung, but does influence the results of the endobronchial approaches.
ENDOBRONCHIAL VALVES
The use of endobronchial blockade was the first alternative therapy to LVRS developed for emphysema ( Fig. 1 ). Sabanathan was the first to attempt EBV placement and is the primary developer of the current Zephyr Valve (Pulmonx). His preliminary work between November 1996 and April 1997 used an EBV system. 34 The design and concept of Sabanathan's EBV was patented and has undergone several subsequent revisions. Although Sabanathan published his work using humans, the first generation of the Zephyr valve (formerly Emphasys) was initially tested in sheep. There were no deployment problems. The literature reported that atelectasis was demonstrated in 90% of the cases. Dislodgement did occur with coughing, which led to the development of version 2 of the device. 35 This newer version was then used in most human pilot studies (Fig.  1C ). The device consists of a 1-way duck-billed valve inside a stainless-steel cylinder attached to a nickel-titanium (nitinol) selfexpanding retainer. It is covered with silicone to create a seal between the valve and the bronchial wall. When the valve is delivered into a targeted bronchus, the retainer expands and comes in contact with the wall of the lumen. It is designed to allow air to flow away from the isolated lung, whereas preventing refilling during inspiration. Two sizes are available: 4.0 (designed for bronchial lumens with a diameter of 4.0 -7.0 mm) and 5.5 (designed for bronchial lumens with diameters of 5.5-8.5 mm). The device is delivered through a catheter which is made of flexible stainless steel and a polymer composite. There is a releasing handle on the proximal end and a housing containing the compressed valve on the distal end. A gauge on the distal housing allows for bronchial diameter measurements. This gauge can be read visually via the bronchoscope. For placement, the loaded catheter is advanced to the targeted location and the valve is delivered by squeezing the deployment handle which retracts the housing and releases the valve. The delivery catheter fits through a 2.8-mm diameter bronchoscope. Currently, the valve has been placed in more than 100 patients in multiple pilot studies. Selection criteria for these patients are similar to those with LVRS, mostly including predominant upper lobe heterogeneous emphysema.
The first report utilizing the Emphasys (later known as Zephyr) valve was by Snell et al. The authors demonstrated that the valve could be deployed safely into the segmental bronchi of 10 patients with symptomatic improvement reported in 40% of those treated. Initial efficacy at 1-month follow-up was accompanied by no major radiographic changes, spirometry changes, or 6-minute walk distance (6MWD) improvement. The DLCO was noted to improve significantly from 7.47 min Ϫ1 ⅐mm Hg Ϫ1 (Ϯ2) to 8.26 mL⅐min Ϫ1 ⅐mm Hg Ϫ1 (Ϯ2.6) (P ϭ 0.04) and on technetium scan, perfusion of the upper lobes decreased significantly from 32 (Ϯ11%) to 27 (Ϯ8%) at 30 days (P ϭ 0.02). These data suggested that EBV placement was feasible and safe, and it may provide benefits similar to LVRS. 5 In a subsequent study by Toma et al, 8 patients with severe heterogeneous emphysema, demonstrated by high resolution computed tomography and ventilation perfusion scintigraphy, underwent EBV therapy. All patients had severe dyspnea on exertion despite maximum medical treatment that included 6 weeks of pulmonary rehabilitation. The median FEV1 for these patients was 0.79 L (24% predicted). Mean residual volume (RV) and DLCO was 273% and 35% predicted, respectively. Once again the overall safety of EBV placement was demonstrated. Two of 8 patients (25%) developed an ipsilateral pneumothorax, whereas 3 of 8 patients (37.5%) had an exacerbation of their COPD. One patient had a transient episode of cough. Follow-up bronchoscopy at 1 month revealed no migration of the EBV. Four of the 8 patients (50%) demonstrated atelectasis, and this correlated with improvement in FEV1. Even those who did not obtain atelectasis still had some improvement of their FEV1. The authors again demonstrated the feasibility and safety of the placement of EBVs. Although there was a 25% pneumothorax rate, this was considered a minor complication. 6 Yim et al placed EBVs in 21 patients in a prospective nonrandomized longitudinal cohort study to demonstrate short-term efficacy (90 days). No mortality was reported. There was significant improvement in mean FEV1 and FVC (0.190 L, P ϭ 0.009 and 0.310 L, P ϭ 0.015, respectively). The 6MWD improved at 30 and 90 days (55 m, P ϭ 0.012 and 71 m, P ϭ 0.003, respectively). The results of SGRQ also showed significant improvement at 90 days (Ϫ23.4 points, P ϭ 0.003). This was the first study to show not only spirometric improvement but also improvement in endurance and quality of life. 7 Additional work with EBVs has been published by Venuta et al and Oliveria et al for an additional cohort of 32 patients. 8, 9 A recent cumulative review of 98 patients recruited at various centers and from several countries that were treated with the initial Emphasys and later Zephyr valve suggests that greater improvement can be obtained if lobar exclusion was achieved. When EBVs were placed in patients with unilateral lobar disease with a baseline FEV1 of Ͻ30% and/or a residual volume of Ͼ225%, significant functional improvement was achieved. Overall, 46% of the patients demonstrated a clinically significant improvement in their FEV1 Ͼ15% and 55% had an improvement of Ͼ15% or 50 m in their 6MWD 90 days after procedure. These statistics were encouraging and suggested patient selection and treatment approach could influence outcomes. 10 The Valve for Emphysema PalliatioN Trial (VENT) study was recently completed. Enrollment included 491 patients in the United States and Europe. Both the treatment and control groups received optimal medical management treatment, including pulmonary rehabilitation. Patients in the treatment group went on to receive EBV therapy with the Zephyr Endobronchial Valve. Results of the VENT study have not yet been released and published, though there are available data regarding these studies at the fda.gov site. FDA approval for use has been sought, but this has not been granted. Based on the available data, it appears that VENT met both its primary efficacy endpoints in regards to showing statistically significant improvements in lung function (FEV1) (P ϭ 0.0047) and exercise tolerance (6MWT) (P ϭ 0.0073) at 6 months, but with suggestions that these improvements are not well sustained at 12 months. Additionally, these differences did not reach the clinical significance level of 15% as prespecified in the initial protocol. Greater improvements in FEV1 (21% increase) were reported in those patients defined as having physiologically isolated target lung zones and correct Zephyr valve placement (P Ͻ 0.0001). Protocol defined major complications occurred in 5.9% of treated patients compared with 1.0% of controls which was not statistically significant. 36 The European arm of the study was not pooled with the US arm of the study. The European arm of the study reportedly had a statistically significant difference in the rate of major complications, with 13.5% in the treatment group and 3.3% in the control group (P ϭ 0.0348).
Although not yet approved in the United States, the Zephyr valve is approved in Europe for emphysema.
The Spiration Valve (Spiration, Redmond, WA) is the only other EBV available and is currently undergoing clinical trials. This valve (Fig. 1A) is an umbrella shaped valve consisting of a nitinol frame with 6 struts (1 center strut surrounded by 5 outer struts). The outer struts are flexible and covered with a thin membrane which when held against the airway wall prevents distal airflow entry. Air, fluid, or mucus can move past the valve with cough or exhalation, but the valve expands during inspiration. They come in multiple sizes and are compressed into a deployment catheter for delivery by means of a working channel of the bronchoscope. Similar to the Zephyr Valve it comes with an airway sizing kit. It is recommended that the valves be deployed under general anesthesia with endotracheal intubation.
Clinical studies with the Spiration Valve began in 2004. 11 Wood et al published a report on the first 30 subjects treated with bilateral upper lobe predominant emphysema. Valves were placed to treat all segments of the right and left upper lobes. BLVR demonstrated an improvement in quality of life as measured by the SGRQ (Ϫ6.8 points, P ϭ 0.05), but did not have a reduction in total lung volume nor an improvement in FEV1 or 6MWD. Placement of the valves was considered safe. No patients experienced a pneumothorax. There was a 6% pneumonia and bronchospasm rate. 12 Based on these initial findings, additional patients were recruited and are part of an ongoing clinical trial.
Available information on the first 98 patients treated with the Spiration Valve, suggests that when endobronchial obstruction achieves greater atelectasis there is an improved treatment response, but also a higher risk of pneumothorax. The initial 30 patients reported by Wood et al did not achieve any significant atelectasis, Clinical Pulmonary Medicine • Volume 17, Number 5, September 2010
Endoscopic Lung Volume Reduction however, in the 68 subsequent patients there were 8 episodes of pneumothorax. When lingular segments were added to the bilateral treatment protocol, greater atelectasis of the left upper lobe was observed, with 6 of 18 patients developing a left-sided pneumothorax. The efficacy findings in these 98 patients confirm the finding of the first 30 patients, with improvement in quality-of-life parameters based on the SGRQ, but not in spirometry and exercise performance. 13 Quantitative computed tomography analyses of these patients have been reported and demonstrated no change in total lung volume (TLV). However, Quantitative computed tomography scans confirmed at 6 months that the treated lobes decreased in mean volume (0.335 L, P Ͻ 0.01) whereas the untreated lobes increased in mean volume (0.374 L, P Ͻ 0.01). These interlobar volume shifts resulted in no change in TLV, but were found to correlate with SGRQ improvement (P Ͻ 0.01). 14 
AIRWAY BYPASS
Airway bypass (Broncus Technologies Inc) is another technology currently being evaluated in the treatment of severe emphysema. It involves the use of a drug eluting stent placed after creating a transbronchial passage through the bronchial wall (Fig. 1B) . This extra-anatomic passageway allows hyperinflated lung regions to decompress. Initial feasibility studies were performed in lungs removed after transplantation. 15 In a subsequent study, also performed on lungs removed following lung transplantation, airway bypass decreased flow resistance, and hyperinflation decreased by a mean of 1.54 L (64%), whereas vital capacity increased by 1.3 L (132%). 16 Canine models were then used to assess both the safety and feasibility of airway bypass. A patented bronchoscopic Doppler probe was used to identify and prevent injury to adjacent blood vessels prior to the creation of an airway bypass tract. The bypass tract was produced using a 22-gauge endobronchial needle and a 2.5-mm angioplasty balloon. A balloon expandable stainless-steel stent covered with silicone was placed within the newly created tract. Seventy stents were placed into 12 dogs and subsequently followed to assess stent patency. One pneumothorax occurred during placement. Thirty-five of the stents were treated with mitomycin C versus 35 untreated controls. All the control stents were occluded at 1-week follow-up. Stents treated with mitomycin C were found to remain patent after more than 20 weeks. These findings confirmed that mitomycin treated stents had greatly improved patency. It also demonstrated that airway bypass was both feasible and safe. 17 Following the results of this study, an investigation was undertaken to determine whether Paclitaxel eluting stents would prevent restenosis, as had been demonstrated in coronary artery stents. Another canine model was designed, and 50 control stents were compared with 170 Paclitaxel drug eluting stents in 25 dogs, with each dog having both control and drug eluting stents. There were no complications with stent placements. The patency rates of the control stents were followed for 12 weeks. All controls were occluded by the fourth week of evaluation, whereas 65% of the drug eluting stents remained patent after 12 weeks. 18 A human study utilizing airway bypass was designed in which 10 patients were treated during lobectomies for neoplasm. The procedure was done after thoracotomy, prior to resection, and limited to the areas in which the lung was going to be removed. Another 5 patients undergoing lung transplantation for emphysema also underwent the creation of an accessory airway bypass. There were 2 incidences of bleeding in those undergoing lobectomy. Bleeding was treated with topical application of epinephrine without further incidence. No bleeding occurred in bypass tracts created prior to lung transplantation. 19 In another study, 35 subjects in 7 centers underwent accessory bypass tract creation and stent placement. Most patients had homogeneous emphysema. Two hundred sixty-four stents were placed with a median of 8 stents per patient. Bleeding resulted in the death of 1 patient, and led to a procedural modification using a bronchus blocking balloon and the addition of a second scan after creation of the bypass tract. One month follow-up demonstrated improvements in RV, TLC, FVC, FEV1, as well as Medical Research Council (MRC) dyspnea scale, 6MWD and SGRQ. The subjects were divided into 2 groups based on whether their baseline RV/TLC ratio was above or below the median for the entire cohort. In subjects who had a baseline RV/TLC ratio above the median the mean RV was reduced by 1.04 L at 1 month and 0.870 L at 6 months. 20 These preliminary clinical results supports further evaluation, which has led to the creation of the Exhaled Airway Stent for Emphysema (EASE) Trial. The EASE Trial is a prospective, multicenter, randomized, double-blind, sham-controlled study to assess the safety and effectiveness of airway bypass in homogenous emphysema. The trial has completed enrollment and is currently ongoing.
BIOLOGIC LUNG VOLUME REDUCTION
Biologic lung volume reduction is also currently in clinical trials. This technology uses patented hydrogel foam (Aeris Therapeutics) that is administered bronchoscopically into the small airways and alveoli. This hydrogel polymerizes to form soft elastic adhesive foam. Initially, clinical trials with this system were conducted in sheep. 37, 38 Ingenito et al reported the effectiveness of lung volume reduction in sheep using a biologic agent in which they targeted specific lung segments. The hydrogel produced scarring and contraction of the pulmonary parenchyma, leading to atelectasis. They reported the gross and microscopic examination of these airways on autopsy of the sheep which confirmed that airway collapse had occurred and that atelectasis was achieved not only because main airways had become obstructed but the channels of collateral ventilation had also been filled with the hydrogel. Atelectasis and lung volume reduction was achieved over a 4 to 8 week period of time as inflammatory changes led to permanent scarring. They reported that lung volume reduction persisted for at least 6 months. 38 Reilly et al described the first utilization of this hydrogel in humans, in an open labeled phase I trial conducted in 6 patients with heterogeneous emphysema. Three patients received unilateral treatment in 2 subsegments whereas another 3 patients received unilateral treatment in 4 subsegments. The authors report no serious adverse events during a 3-month follow-up. Minor complications included blood streaked sputum (4 patients), cough (3 patients), chest soreness (3 patients), COPD exacerbation (2 patients). Physiological responses in FEV1, DLCO, or arterial blood gases were not statistically significant. Also, a significant difference in dyspnea score was not achieved. Only 1 patient achieved a clinically significant improvement in 6MWD. Based on this study, the authors felt that biologic lung volume reduction could be performed safely and could produce benefits in appropriately selected patients with heterogeneous emphysema. 39 Criner et al reported the results of a phase II trial using biologic lung volume reduction. Patients were randomized to receive either low dose (10 mL of hydrogel per subsegment) or high dose (20 mL of hydrogel per subsegment) treatment. Twenty-eight patients received low dose whereas 22 patients received high dose treatment. No deaths were encountered in either group. There were only 3 serious adverse events. Two patients developed myocardial infarction, but it was unclear whether this was related to the treatment. One patient developed pneumonia. Minor complications included leukocytosis and fever. With regards to efficacy, at 6 weeks, there were statistically significant increases in spirometry, a reduction in dyspnea and improvement in the health related quality of life index scores. At 6 months, the low dose group maintained a FEV1 better than at baseline, but improvements in other spirometric variables were no longer statistically significant. All physiological outcome measures remained statistically improved as compared with baseline in the high dose patients. The mean improvement in FEV1 at 6 months was 15.6% (Ϯ16.8). The authors concluded that biologic lung volume reduction improves both physiological and functional outcomes up to 6 months, with acceptable safety. Upper lobe predominant heterogeneous emphysema patients derived the most benefit. Additionally, a more durable response was demonstrated when dosing 20 mL as compared with 10 mL of hydrogel. 21 Phase III studies using hydrogel to achieve biologic lung volume reduction are currently ongoing in Europe. A different polymer is being used in the current European trials (personal communication).
NEW TECHNOLOGIES
Other technologies being considered for lung volume reduction include the use of thermal vapor to achieve ablation in heterogeneous emphysema with upper lobe predominance. Treatment involves timed delivery of thermal vapor at a prescribed temperature. The results of the first 20 patients in whom this technology has been used can be found in abstract form only. Early results suggest that it is feasible and has acceptable safety. Adverse events associated with this approach include 3 of the 20 patients (15%) develop-ing a COPD exacerbation, and 1 patient developing hemoptysis. At 30-day follow-up, FEV1 improved by 13.4%, FVC by 6.3%, and RV decreased by 7.9%. 22 Follow-up of these patients continues.
A nitinol endobronchial coil system (Pneumrx, Mountain View, CA) is also in early development. This coil is maintained in a straightened position and deployed in the distal airway via a guided sheath (Fig.  1D) . Placement is directed via fluoroscopy. On release, the nitinol coil collapses the distal airways resulting in lung volume reduction. Eleven patients have been treated to date receiving 8 to 11 coils; 6 patients were treated bilaterally. Adverse events include dyspnea (4 patients), cough (4 patients), and COPD exacerbation (1 patient). Efficacy of this system has not yet been reported. 23 In addition to the technologies described, a system to evaluate the presence of CV is being developed by makers of the Zephyr Valve, known as Chartis (Fig. 2) . This technology currently has been used in 17 patients. A catheter is placed in the segment of the lung in which treatment is anticipated and then airflow and resistance are measured to determine whether CV is present. In the 17 patients evaluated using the Chartis system, resistive measurements correlated with initial chest x-rays and with the development of atelectasis after placing the valves. 40 It is hoped that by using this Endoscopic Lung Volume Reduction technology, treatment of appropriate segments can be specifically targeted (ie, those without collateral ventilation will be more susceptible and appropriate for treatment with endobronchial valves to produce significant atelectasis to decrease hyperinflation). This study is currently underway.
DISCUSSION
It is clear that there has been significant progress in the development of new modalities for treatment of patients with advanced emphysema. The Emphasys and Spiration Valve have been demonstrated to be both feasible and reasonably safe. This technology is attractive to physicians as EBVs can be easily removed. The longest duration of EBV placement and subsequent removal is reportedly 4 years. Current efficacy data associated with the use of EBVs are available in only a small number of patients. All the available studies suggest that for the most part patients obtain minimal improvements in their FEV1 and FVC whereas certain others attain spirometric measurements comparable to LVRS. It is concerning that these spirometric improvements cannot be reliably duplicated in all patients. The inability to achieve predictable treatment outcomes limits the generalization of this technology for patients with heterogeneous emphysema. For this reason, improved identification of those patients that will benefit from EBV placement is needed. The presence of CV has been shown to preclude adequate response to the placement of EBV, by allowing areas of the lung beyond the valve to remain inflated. Although this may be viewed as a negative condition, it actually helps prevent the development of secondary procedure-related pneumothoraces. Pneumothorax associated with BLVR is considered by some investigators a minor complication and perhaps necessary. Most require no additional treatment (ie, the placement of a chest tube).
It is generally felt that knowledge of the amount of CV may assist in targeting therapy. A consistent way to evaluate the presence and amount of CV is currently being sought. If CV can be reliably assessed, then subgroups of patients which may benefit from EBV placement may be more easily identified. Long-term complications of EBVs such as granulation tissue formation, infection, or bleeding have not been reported; however, isolated personal reports from physicians participating in the original EBV studies suggest that granulation and chronic infection can occur (personal communication).
Increases in endurance and quality of life have also been demonstrated with EBV technology, although again these measurements cannot be consistently reproduced. It is perhaps necessary to consider that spirometry may not be an appropriate study end point for EBV technology and that functional or quality of life measurements may better reflect the benefits of EBVs. The data from VENT study suggest that further investigation is necessary with the Zephyr valve. The available results need to also be evaluated carefully, understanding that this trial was not blinded, and hence is subject to bias. The initial Spiration trial reported an improvement in quality of life despite no clinically significant improvement in spirometry or exercise capacity. 12 Was this a so-called "placebo effect" or a true benefit? It remains unclear whether these findings will be duplicated in Spiration's current ongoing randomized control trial. In summary, EBV technology has not yet been approved in the United States for the treatment of emphysema and patients should only receive these in the context of ongoing research trials. Whether EBV technology will achieve the outcomes of LVRS is uncertain, but if it offers improvements with acceptable risk then it may well prove to be a treatment option in selected patients. It is also not known whether EBVs could be used in patients not suitable for LVRS. It is important to mention that although no EBV has received FDA approval, the Spiration Valve did receive a Humanitarian Device Exemption for the treatment of persistent air leaks following lobectomy, segmentectomy, and LVRS. 41 The creation of an airway bypass tract is less appealing than placement of an EBV, primarily because of the lack of reversibility. Patients undergoing bypass tract creation require intubation and anesthesia which may pose addition risks. Although endobronchial stents can be removed and restenosis of the bypass tract will likely occur, the long-term complications of this technology remains unknown. Creation of bypass tracts is associated with a significantly higher morbidity when compared with EBVs. The recently published Phase II report of this technology suggests a rather high number of COPD exacerbations, as well as a substantial incidence of pneumomediastinum and pneumonia. Arguably, this is a new procedure and with continued technical improvements a decrease in these associated morbidities may occur. When considering the complications associated with airway bypass in regards to the available efficacy, this technology currently poses a high risk to benefit ratio. Because of the need to use several drug eluting stents per patient, the price of this therapy may not prove to be cost effective. Additionally, stenosis of the bypass tracts, either distal or proximal to the stent, could occur and how this will impact their use remains unknown. The EASE study has been completed and hopefully will shed additional light on the current safety and usefulness of this treatment option. For now, this endobronchial approach should not be offered outside of clinical trials.
Although biologic lung volume reduction with hydrogel remediates the problems of CV that have been associated with EBV technology, Phase II trial outcomes suggest a higher morbidity with similar efficacy when compared with EBVs. Biologic lung volume reduction is also irreversible. Higher dosing with hydrogel appears to be more efficacious in both spirometric responses and quality of life. If greater efficacy could be demonstrated in the ongoing clinical trials, then perhaps an acceptable risk to benefit ratio could be achieved. Higher morbidity has also been suggested with thermal vaporization ablation. There have only been a few patients treated with these 2 technologies. Both approaches are similar in that they attempt to achieve BLVR by creating targeted distal airway obstruction which occurs over time. This is done by producing inflammatory changes within these targeted airways that result in remodeling. Both technologies also obviate the concerns associated with CV. However, their difficulty is perhaps in controlling the inflammatory response. Inflammation, which is necessary to produce remodeling, can also lead to an acute exacerbation. Low level bacterial colonization which has been demonstrated in this patient population may result in the development of pneumonia when treated by these 2 approaches. The effects of steroids and antimicrobials preprocedure, periprocedure, and postprocedure in patients undergoing biologic lung volume reduction or thermal vaporization ablation remains unexplored. A determination of bacterial colonization and subsequent treatment with antimicrobials prior to utilizing these approaches may or may not affect the incidence of pneumonia. Clinical trials continue to explore these 2 new approaches to BLVR.
Endobronchial coiling as a means of BLVR is currently in the early stages of development. It has advantages similar to EBVs in its reversibility. Efficacy outcomes have not been reported. Adverse events thus far are not major, but patient numbers remain small. Certainly ongoing studies are necessary. It is too early to make any recommendations regarding use outside of clinical trials.
Improvements in trial design are necessary as BLVR technology continues to develop and seeks to gain approval by both physicians and patients. Appropriate endpoints for efficacy need to be considered. Spirometry and lung volumes may not adequately represent those patients that benefit the most from BLVR. Endpoints based on quality of life measurements, such as dyspnea, and per-formance, such as exercise capacity, perhaps better reflect the goals of BLVR. These endpoints are the most important to our patients and conceivably should be given the greatest consideration. Each of the reviewed BLVR technologies should consider establishing comparable primary and secondary endpoints. Varying trial designs with different primary and secondary endpoints currently make comparison impossible. Investigators should examine the utility of "sham bronchoscopy" as a means of providing for an acceptable control group. Until such improvements are made, research in BLVR is likely to be viewed with some degree of skepticism.
Additionally, the identification of subgroups that receive the greatest benefit as well as those who may be at risk for adverse events should continue to be explored. The use of multimodalities should also be considered, as this may provide for a greater number of patients who could benefit from treatment which would have been excluded on the basis of a single modal approach.
With all things considered, the lessons of LVRS should serve to caution practitioners that whereas we search for an acceptable endoscopic approach to lung volume reduction, we should refrain from wholly adopting any technology until it can be fully explored. The number of patients with emphysema is great and their willingness to undergo any procedure to improve quality of life could expose them to unnecessary risks. For now, our patients are best served by ongoing clinical trials.
